Sponsored by:

Molecular Imaging: Page 444

ART scores two Optix orders
By AuntMinnie.com staff writers
Medical device firm ART Advanced Research Technologies of Montreal received two orders for its Optix MX2 preclinical optical molecular imager, the company said.
December 5, 2007
Bristol-Myers Squibb to divest imaging unit, including Cardiolite radiopharmaceutical
By Brian Casey
Pharmaceutical giant Bristol-Myers Squibb is planning to sell off its medical imaging unit as part of a restructuring of the New York City-based company. The firm's medical imaging division markets the Cardiolite technetium-based radiopharmaceutical, as well as other radiopharmaceuticals and ultrasound contrast media.
December 4, 2007
MDS Nordion divests two product lines
By AuntMinnie.com staff writers
Radioisotope developer MDS Nordion of Kanata, Ontario, announced the sale of its external beam therapy and self-contained irradiator product lines in a move to focus the firm's resources on molecular medicine initiatives.
November 29, 2007
PET does not predict survival in advanced lung cancer
By Eric Barnes
CHICAGO - Studies over the past several years have demonstrated FDG-PET's ability to predict survival in patients with early-stage lung cancer. But for those with advanced non-small cell lung cancer (NSCLC), PET has no prognostic value, according to a new 15-year study from Duke University Medical Center in Durham, NC.
November 28, 2007
Triple-negative breast cancers show marked clinical features
By Kate Madden Yee
CHICAGO - Women diagnosed with triple negative (TN) breast cancer -- in which the tumor is estrogen receptor-negative, progesterone receptor-negative, and HER2-negative -- tend to have fewer treatment options and worse prognoses than women with non-TN tumors. But certain characteristics and imaging features may help clinicians diagnose these tumors earlier, according to a presentation at the RSNA 2007 meeting.
November 28, 2007
Neoprobe, Cardinal Health ink distribution deal
By AuntMinnie.com staff writers
Gamma camera probe developer Neoprobe has signed a distribution agreeement with healthcare products firm Cardinal Health, also of Dublin, for the marketing and distribution of its Lymphoseek radiopharmaceutical through Cardinal's network of more than 150 nuclear pharmacies.
November 27, 2007
Draxis breaks ground for new facility
By AuntMinnie.com staff writers
Canadian radiopharmaceutical developer Draxis Health of Mississauga, Ontario, reported it has started construction of its second packaging and warehousing facility in Montreal.
November 26, 2007
FDG-PET/CT accurately detects inflammatory breast cancer
By Edward Susman
CHICAGO - The use of FDG-PET/CT with patients with inflammatory breast cancer can accurately detect and help treat the deadly disease, according to a study by researchers at the University of Texas M. D. Anderson Cancer Center in Houston. They presented their findings at the RSNA 2007 meeting on Tuesday.
November 26, 2007
IBA, PETLinQ acquire SourceMedical's radiology division
By AuntMinnie.com staff writers
IBA Molecular, North America and PETLinQ have acquired the radiology division of SourceMedical. The acquisition will expand the companys' product line to include the SourceRad RIS and billing system.
November 25, 2007
New contrast agent could replace some nuclear stress testing with echo
By Eric Barnes
Researchers in the U.K. believe that an investigative echocardiography contrast agent could soon be used to replace nuclear cardiography stress exams for the initial detection of coronary artery disease. Their preliminary results of two trials suggest that perfusion stress echocardiography is as accurate as nuclear stress testing for detecting coronary artery disease.
November 21, 2007
Lack of IV contrast causes discrepancy in CT with PET scans
By Wayne Forrest
A study to determine the diagnostic limitations of low-dose, unenhanced CT scans performed for anatomic reference and attenuation correction during PET/CT has found that most discrepancies were due to the lack of intravenous contrast, which obscured liver metastases and lymph node recognition.
November 21, 2007
2007 11 21 16 05 05 706
Siemens makes FLT available to NCI research sites
By AuntMinnie.com staff writers
Siemens Medical Solutions said that the U.S. National Cancer Institute (NCI) has filed a cross-reference letter related to the company's investigational F-18 FLT imaging biomarker.
November 20, 2007
Previous Page
Page 444 of 609
Next Page